Compound Evidence File
#EC-2026-0403
Pancragen
Filed under Peptides. The bureau holds 151 laboratory returns for this compound from 63 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
63 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 8 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 25 May 2026 | 25 May 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 10.0 | 10.0 | 10.0 | 19 Mar 2026 | 16 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 10.0 | 10.0 | 9 Apr 2026 | 3 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 10.0 | 9.9 | 10.0 | 19 Feb 2026 | 14 Aug 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 3 | 10.0 | 9.9 | 10.0 | 19 Jun 2026 | 4 Aug 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 10.0 | 9.9 | 10.0 | 23 Feb 2026 | 5 May 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 10.0 | 10.0 | 10.0 | 28 May 2026 | 14 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 9.9 | 9.9 | 10.0 | 3 Dec 2025 | 20 Apr 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 9.9 | 9.9 | 10.0 | 4 Dec 2025 | 18 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 9.9 | 9.9 | 10.0 | 18 Jan 2026 | 17 Jun 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 9.9 | 9.9 | 10.0 | 25 May 2026 | 15 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 9.9 | 9.9 | 10.0 | 17 Feb 2026 | 24 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 9.9 | 9.9 | 10.0 | 4 Mar 2026 | 6 Aug 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 4 | 9.9 | 9.9 | 10.0 | 23 Apr 2026 | 19 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 9.9 | 9.9 | 10.0 | 13 Feb 2026 | 6 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 9.9 | 9.9 | 10.0 | 3 Apr 2026 | 10 Jun 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 9.9 | 9.9 | 10.0 | 20 Apr 2026 | 6 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 9.9 | 9.9 | 10.0 | 8 Feb 2026 | 9 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 3 | 9.9 | 9.9 | 10.0 | 9 Feb 2026 | 19 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 10.0 | 21 Apr 2026 | 6 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 9.9 | 9.9 | 9.9 | 10 Jan 2026 | 24 Jun 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 2 | 9.9 | 9.9 | 10.0 | 25 Apr 2026 | 9 Aug 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 4 | 9.0 | 7.8 | 9.8 | 25 May 2026 | 25 May 2026 |
| HkRoidsCASE #VI-2026-0784 | X | 1 | 8.8 | 8.8 | 8.8 | 3 Jul 2025 | 3 Jul 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 5 | 8.6 | 8.3 | 8.9 | 23 May 2026 | 23 May 2026 |
| CellupepCASE #VI-2026-0888 | X | 1 | 8.5 | 8.5 | 8.5 | 9 Jun 2025 | 9 Jun 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 7 | 8.4 | 7.7 | 9.8 | 24 May 2026 | 24 May 2026 |
| Yongkang Nuoao Trading CoCASE #VI-2026-0646 | X | 1 | 8.2 | 8.2 | 8.2 | 8 Jul 2025 | 8 Jul 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 2 | 8.0 | 7.1 | 8.9 | 24 May 2026 | 24 May 2026 |
| Allen Biotechnology Co ABCCASE #VI-2026-0709 | X | 4 | 8.0 | 5.2 | 10.0 | 16 Mar 2025 | 17 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 5 | 7.9 | 6.4 | 8.8 | 23 May 2026 | 23 May 2026 |
| Golden EagleCASE #VI-2026-0680 | X | 1 | 7.9 | 7.9 | 7.9 | 9 Jun 2025 | 9 Jun 2025 |
| Shanghai Leader Peptide BiotechnologyCASE #VI-2026-0558 | X | 1 | 7.9 | 7.9 | 7.9 | 8 Jul 2025 | 8 Jul 2025 |
| Qingdao Hongshengda TradingCASE #VI-2026-0334 | X | 1 | 7.8 | 7.8 | 7.8 | 13 Feb 2025 | 13 Feb 2025 |
| Champion PeptideCASE #VI-2026-0909 | X | 1 | 7.8 | 7.8 | 7.8 | 14 Jan 2025 | 14 Jan 2025 |
| HazelCASE #VI-2026-0392 | X | 1 | 7.7 | 7.7 | 7.7 | 24 Apr 2025 | 24 Apr 2025 |
| Huayi BiotechnologyCASE #VI-2026-0243 | X | 1 | 7.6 | 7.6 | 7.6 | 13 Jun 2025 | 13 Jun 2025 |
| Astro PeptidesCASE #VI-2026-0424 | X | 2 | 7.2 | 7.2 | 7.3 | 25 Apr 2025 | 24 May 2026 |
| Pura PeptidesCASE #VI-2026-0307 | X | 1 | 7.0 | 7.0 | 7.0 | 24 Apr 2025 | 24 Apr 2025 |
| Xingtai Jiachuang TechnologyCASE #VI-2026-0712 | X | 3 | 6.7 | 5.5 | 8.3 | 2 Apr 2025 | 24 May 2026 |
| Shaanxi Dideu MedichemCASE #VI-2026-0499 | X | 1 | 6.5 | 6.5 | 6.5 | 17 Dec 2024 | 17 Dec 2024 |
| Chimera PeptidesCASE #VI-2026-0260 | X | 1 | 6.3 | 6.3 | 6.3 | 14 Jan 2025 | 14 Jan 2025 |
| Eternal PeptidesCASE #VI-2026-0842 | X | 2 | 6.1 | 5.8 | 6.4 | 28 Mar 2025 | 20 May 2026 |
| Shandong Aishi BiotechnologyCASE #VI-2026-0308 | X | 3 | 6.0 | 4.7 | 6.7 | 9 Jun 2025 | 24 May 2026 |
| Tianjin Ruiwang New Material Technology CoCASE #VI-2026-0192 | X | 1 | 5.6 | 5.6 | 5.6 | 2 Jul 2025 | 2 Jul 2025 |
| PurePeptidesCASE #VI-2026-0234 | X | 1 | 5.6 | 5.6 | 5.6 | 28 Mar 2025 | 28 Mar 2025 |
| ZhuoYan labCASE #VI-2026-0902 | X | 3 | 5.5 | 4.4 | 6.6 | 13 Jun 2025 | 17 May 2026 |
| Zhejiang Yichenkang BiotechnologyCASE #VI-2026-0269 | X | 2 | 5.3 | 3.4 | 7.2 | 14 Jan 2025 | 24 May 2026 |
| Royal PeptidesCASE #VI-2026-0264 | X | 1 | 4.8 | 4.8 | 4.8 | 3 Jul 2025 | 3 Jul 2025 |
| Dragon PharmaCASE #VI-2026-0519 | X | 1 | 4.7 | 4.7 | 4.7 | 7 May 2025 | 7 May 2025 |
| Precision Peptide CoCASE #VI-2026-0559 | X | 1 | 4.7 | 4.7 | 4.7 | 21 May 2025 | 21 May 2025 |
| Liberty PeptidesCASE #VI-2026-0416 | X | 1 | 4.5 | 4.5 | 4.5 | 17 Dec 2024 | 17 Dec 2024 |
| Xian Yihang TechnologyCASE #VI-2026-0656 | X | 2 | 4.4 | 3.8 | 5.1 | 3 Jun 2025 | 24 May 2026 |
| PeptiLab ResearchCASE #VI-2026-0267 | X | 1 | 3.7 | 3.7 | 3.7 | 16 Mar 2025 | 16 Mar 2025 |
| Guangzhou Lengiuanhuang CosmeticsCASE #VI-2026-0228 | X | 1 | 3.4 | 3.4 | 3.4 | 3 Jun 2025 | 3 Jun 2025 |
| WllyBIOCASE #VI-2026-0470 | X | 1 | 3.3 | 3.3 | 3.3 | 17 Dec 2024 | 17 Dec 2024 |
| Explicit SarmsCASE #VI-2026-0017 | X | 1 | 0.5 | 0.5 | 0.5 | 20 Jun 2025 | 20 Jun 2025 |
| LOOKBiotechCASE #VI-2026-0807 | X | 1 | 0.2 | 0.2 | 0.2 | 2 Jul 2025 | 2 Jul 2025 |
| Weifang Xingbei International TradeCASE #VI-2026-0766 | X | 1 | 0.0 | 0.0 | 0.0 | 14 Jan 2025 | 14 Jan 2025 |
| Wuhan Newtop BiotechCASE #VI-2026-0676 | X | 1 | 0.0 | 0.0 | 0.0 | 16 Mar 2025 | 16 Mar 2025 |
| Lejian Biotech PeptideCASE #VI-2026-0746 | X | 1 | 0.0 | 0.0 | 0.0 | 3 Jun 2025 | 3 Jun 2025 |
| PRIVATECASE #VI-2026-0635 | X | 1 | 0.0 | 0.0 | 0.0 | 16 Mar 2025 | 16 Mar 2025 |
Open any subject to view the batch-level evidence for Pancragen alone.